China is a good cyclical market to play; India still most expensive market relative to other EMs. Arjun Divecha, Partner and Head of Emerging Markets at Boston-based investment firm GMO, is in the middle of roadshows across North America for his newly launched fund, ‘Beyond China’ The fund aims to invest in countries benefiting from the ‘China plus one’ supply chain diversification strategy. Given that India stands to gain from this long-term trend, the fund will include Indian investments. Divecha currently holds zero weight in India across his emerging market portfolios, primarily due to high valuations. In a free-wheeling conversation, Divecha talks about his new fund, his take on India Vs China, foreign selling and Trump policies. He also talks about how to trade Emami, Sarda Energy, SRF, Nestle India, InterGlobe Aviation, J… Trading Plan: Will Nifty 50 manage to defend 22,250, Bank Nifty hold above 48,000?